ACL — Australian Clinical Labs Income Statement
0.000.00%
Last trade - 00:00
- AU$533.34m
- AU$834.98m
- AU$697.07m
- 73
- 70
- 30
- 60
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 448 | 491 | 647 | 996 | 697 |
Cost of Revenue | |||||
Gross Profit | 369 | 404 | 527 | 788 | 571 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 454 | 443 | 538 | 729 | 635 |
Operating Profit | -5.8 | 47.4 | 109 | 267 | 62 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.7 | 30.8 | 86.7 | 255 | 48.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10.5 | 41.3 | 60.4 | 178 | 36 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -10.5 | 41.3 | 60.4 | 178 | 35.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -10.5 | 41.3 | 60.4 | 178 | 35.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.05 | 0.204 | 0.366 | 0.905 | 0.178 |
Dividends per Share |